Trial Profile
Phase II study of VELCADE in combination with Rituximab in patients with relapsed or progressed Non Hodgkin's Follicular Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 11 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01830465).
- 31 May 2011 New trial record